Tuberculosis News and Research

Latest Tuberculosis News and Research

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration has accepted for priority review the company's new drug application for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease.

15 Apr 2013

White House releases FY14 budget request

"The Obama administration released its fiscal year 2014 budget on Wednesday," Devex's "Pennsylvania Ave." blog reports (Lieberman, 4/11).

12 Apr 2013

Opinion pieces urge continued support for Global Fund

This week, the Global Fund to Fight AIDS, Tuberculosis and Malaria gathered representatives from donor and implementing countries in Brussels, Belgium, to formally launch its 2014-2016 replenishment process.

12 Apr 2013

Global Fund concludes 2-day conference in Brussels

In Brussels on Wednesday, "the Global Fund to Fight AIDS, Tuberculosis and Malaria concluded a two-day conference where it tried to make the case for the $15 billion it aims to raise in a replenishment meeting late 2013," Devex reports.

12 Apr 2013

Blogs, press releases respond to Obama administration's FY14 budget request

The Obama administration on Wednesday released its FY 2014 budget request, including funding for U.S. global health activities and proposed changes to the U.S. food aid program.

12 Apr 2013

Researchers unravel dual role of tumor necrosis factor in TB

Tumor necrosis factor - normally an infection-fighting substance produced by the body- can actually heighten susceptibility to tuberculosis if its levels are too high.

12 Apr 2013

Australian, Singapore researchers join hands to combat disease-causing bugs

The fight against a number of significant infectious diseases in the Asia-Pacific region has been given a boost through a new research collaboration between the National Health and Medical Research Council in Australia and the Agency for Science, Technology and Research in Singapore.

12 Apr 2013

Global health efforts a casualty of across-the-board cuts under 'sequester'

"The across-the-board cuts under the 'sequester' will undermine efficient programs, along with the inefficient. One unfortunate casualty is spending on global health efforts," a Pittsburgh Post-Gazette editorial says.

11 Apr 2013

Aidspan publishes new issue of 'Global Fund Observer'

Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, has published Issue 214 of its "Global Fund Observer."

11 Apr 2013

$15B commitment to Global Fund would change the course of history

On Monday "in Brussels, the Global Fund to Fight AIDS, Tuberculosis and Malaria announced an appeal to government and private sector donors for $15 billion for the next three years," Joyce Banda, president of the Republic of Malawi, writes in the Huffington Post's "The Big Push" blog.

11 Apr 2013

Interaction global health briefing book warns of implications from U.S. budget cuts

InterAction, an umbrella group representing 37 non-governmental organizations (NGOs), "is calling on Congress and President Barack Obama's administration to keep spending on global health aid at current levels, warning that recent budget cuts risk a dangerous backslide in health and development gains achieved over the past three decades," Inter Press Service reports.

11 Apr 2013

South Africa announces rollout of new single-dose ARV therapy

"South Africa's Health Minister Aaron Motsoaledi announced on Monday the launch of a new single-dose combination antiretroviral drug that will cost just 89 rand a month ($10) per patient, potentially revolutionizing AIDS treatment in the country," Salon reports (McDonough, 4/9).

11 Apr 2013

Interaction global health briefing provides recommendations to congress, administration

"If the United States does not follow through on global health commitments, there could be a reversal or stagnation of recent gains in reducing maternal deaths and incidences of tuberculosis, malaria, HIV and other diseases in developing countries, warns a report published [Monday]," titled "Global Health: Investing in Our Future," an InterAction press release states.

10 Apr 2013

Study reveals high blood pressure and obesity are no longer confined to wealthy countries

High blood pressure and obesity are no longer confined to wealthy countries, a new study has found. These health risks have traditionally been associated with affluence, and in 1980, they were more prevalent in countries with a higher income.

10 Apr 2013

Five Japanese drug makers form PPP to accelerate development of drugs, vaccines for infectious diseases

"Five Japanese pharmaceutical giants are teaming up with the Bill & Melinda Gates Foundation and Japan's government to develop new medicines, vaccines, and diagnostics for infectious diseases in developing countries," GENNews reports (4/8).

10 Apr 2013

Continued support of Global Fund is worthy investment

Writing in the Huffington Post's "The Big Push" blog, Bill Gates, co-chair of the Bill & Melinda Gates Foundation, examines why the Global Fund to Fight AIDS, Tuberculosis and Malaria is a good investment.

10 Apr 2013

Global Fund aims to raise $15B to fight infectious diseases in 2014-2016 period

"The Global Fund to Fight AIDS, Tuberculosis and Malaria has set the target of raising $15 billion to help countries fight the three infectious diseases in the 2014-2016 period, its Executive Director Mark Dybul said ... on Monday," Xinhua reports.

10 Apr 2013

Research findings could help develop effective vaccines against new strains of bird flu

Scientists have described small genetic changes that enable the H5N1 bird flu virus to replicate more easily in the noses of mammals.

9 Apr 2013

Anacor signs research agreement to discover drug candidates to treat neglected diseases

Anacor Pharmaceuticals today announced that it has signed a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to treat two filarial worm diseases (onchocerciasis, or river blindness, and lymphatic filariasis, commonly known as elephantiasis) and tuberculosis.

9 Apr 2013

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

Professor Alex Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics Centre (ETC), has been awarded the 8th Annual Szent-Gy-rgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research (NFCR) for his contributions to the development of the first drug specifically targeting a molecular lesion in cancer.

7 Apr 2013